Learn about UCSF’s response to the coronavirus outbreak, important updates on campus safety precautions, and the latest policies and guidance on our COVID-19 resource website. You can also access information from the CDC. Learn more
UCSF researchers have leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side effects or complications associated with current treatment regimens.
UCSF and The Atlantic have announced that the crowdsourced digital archive documenting the face of the pandemic in the United States will become part of the University’s permanent library collection and is accessible to researchers and the public.
UCSF researchers in collaboration with the Centers for Disease Control’s Tuberculosis Trials Consortium and the AIDS Clinical Trials Group published a landmark study that demonstrated a new four-month treatment regimen for tuberculosis was safe and as efficacious as the standard six-month therapy.
A UCSF study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.
Researchers at UC San Francisco have successfully developed a “speech neuroprosthesis” that has enabled a man with severe paralysis to communicate in sentences, translating signals from his brain to the vocal tract directly into words that appear as text on a screen.
Children with a devastating genetic disorder characterized by severe motor disability and developmental delay have experienced sometimes dramatic improvements in a gene therapy trial launched at UCSF Benioff Children’s Hospitals.
Plenty of probiotic yogurts, pickles and kombuchas claim to boost our digestive health with armies of microbes, but some scientists have more ambitious therapeutic plans for the “bugs” that colonize us. They hope to leverage these microbes as living therapeutics for a range of health conditions, including ulcerative colitis, multiple sclerosis, eczema and asthma.
Researchers at UC San Francisco have found that extreme caloric restriction diets alter the microbiome in ways that could help with weight loss but might also result in an increased population of Clostridioides difficile, a pathogenic bacterium that can lead to severe diarrhea and colitis.
Individuals with HIV are more than twice as likely to die from sudden cardiac death (SCD) compared to the general population, and more likely to have hearts compromised by fibrosis, a factor that may play a role in increasing their susceptibility to SCD, according to new findings from a UCSF study.
The B.1.1.7 coronavirus variant—also known as Alpha—may be more infectious because it contains mutations that make it better adapted to foil the innate immune system, at least for long enough to allow the virus to replicate and potentially find new hosts, according to a new study.
The viruses that cause polio and COVID-19 mutate, but treatments for the diseases don’t. For over 20 years, UCSF and Gladstone Institutes scientist Leor Weinberger, PhD, has been thinking of ways to make vaccines work more efficiently by being adaptive, rather than static.